Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.

Abstract

INTRODUCTION Vemurafenib induces tumour regression in most patients with BRAF(V600E)-mutant melanoma; eventually, most experience progressive disease (PD). Long-term follow-up of patients with BRAF(V600E) melanoma treated in the phase 1 vemurafenib trial is reported. METHODS Patients received vemurafenib 240-1120 mg (dose escalation cohort) or 960 mg… (More)

DOI: 10.1016/j.ejca.2015.04.010

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Statistics

Citation Velocity

Citations per Year

Citation Velocity: 12

Averaging 12 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cited By

Sort by:

Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis

Ling Peng, Yina Wang, +4 authors Qiong Zhao
Oncotarget
2017

Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma

Jessica C Hassel, Kristina Buder-Bakhaya, +6 authors Ralf Gutzmer
Cancer medicine
2018

A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.

Drew C Deniger, Mei Li M Kwong, +5 authors Steven A Rosenberg
Clinical cancer research : an official journal of…
2017

Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.

Bernard Escudier, Robert J Motzer, +17 authors Saby George
European urology
2017

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib

Paola Queirolo, Francesco Spagnolo, +11 authors Paolo Antonio Ascierto
Oncotarget
2016

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors

Tanja Dolinsek, Lara Prosen, Maja Cemazar, Tjasa Potocnik, Gregor Sersa
Radiology and oncology
2016

Endoplasmic reticulum stress-induced autophagy determines the susceptibility of melanoma cells to dabrafenib

Chao Ji, Ziping Zhang, +6 authors Bo Cheng
Drug design, development and therapy
2016

Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives.

Yoon Young Choi, Sung Hoon Noh, Jae-Ho Cheong
Journal of pathology and translational medicine
2016

The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib

Theresa M Medina, Karl D Lewis
OncoTargets and therapy
2016

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma

Alexander Muacevic, John R Adler, Tania Jain, Alan Bryce
Cureus
2015

References

Sorry, we couldn't extract any references for this paper.

Slides referencing similar topics

Vemurafenib on BRAF-V600 Melanoma Vemurafenib on BRAF-V600 Melanoma
Hoifung Poon • Nov 29, 2017
Prediction of Kidney Disease Progression in Patients with Diabetes
John Arthur • Aug 27, 2017
Long-term Risk of Melanoma-related Mortality in Patients with Uveal Melanoma Treated with Proton Beam Therapy
Evangelos S. Gragoudas • Sep 06, 2017
Show More